174 related articles for article (PubMed ID: 29899862)
1. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.
Hulin-Curtis SL; Davies JA; Jones R; Hudson E; Hanna L; Chester JD; Parker AL
Oncotarget; 2018 May; 9(41):26328-26341. PubMed ID: 29899862
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad.
Strait KA; Warnick CT; Ford CD; Dabbas B; Hammond EH; Ilstrup SJ
Mol Cancer Ther; 2005 Apr; 4(4):603-11. PubMed ID: 15827334
[TBL] [Abstract][Full Text] [Related]
3. HDAC Inhibitors Enhance Efficacy of the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T in Pancreatic and Triple-Negative Breast Cancer Models.
Rodríguez MDCR; Rodríguez IG; Nattress C; Qureshi A; Halldén G
Viruses; 2022 May; 14(5):. PubMed ID: 35632748
[TBL] [Abstract][Full Text] [Related]
4. Impact of the histone deacetylase inhibitor trichostatin A on active uptake, volume-sensitive release of taurine, and cell fate in human ovarian cancer cells.
Lambert IH; Nielsen D; Stürup S
Am J Physiol Cell Physiol; 2020 Mar; 318(3):C581-C597. PubMed ID: 31913698
[TBL] [Abstract][Full Text] [Related]
5. Histone Deacetylase-1-mediated Suppression of FAS in Chemoresistant Ovarian Cancer Cells.
Cacan E
Anticancer Res; 2016 Jun; 36(6):2819-26. PubMed ID: 27272793
[TBL] [Abstract][Full Text] [Related]
6. Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells.
Muscolini M; Cianfrocca R; Sajeva A; Mozzetti S; Ferrandina G; Costanzo A; Tuosto L
Mol Cancer Ther; 2008 Jun; 7(6):1410-9. PubMed ID: 18566213
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines.
Jin X; Fang Y; Hu Y; Chen J; Liu W; Chen G; Gong M; Wu P; Zhu T; Wang S; Zhou J; Wang H; Ma D; Li K
Oncol Lett; 2017 Jun; 13(6):4619-4626. PubMed ID: 28588720
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma
Ma J; Li N; Zhao J; Lu J; Ma Y; Zhu Q; Dong Z; Liu K; Ming L
Oncol Lett; 2017 Jun; 13(6):4868-4874. PubMed ID: 28599488
[TBL] [Abstract][Full Text] [Related]
9. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
Chang J; Varghese DS; Gillam MC; Peyton M; Modi B; Schiltz RL; Girard L; Martinez ED
Br J Cancer; 2012 Jan; 106(1):116-25. PubMed ID: 22158273
[TBL] [Abstract][Full Text] [Related]
10. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
11. GM101 in Combination with Histone Deacetylase Inhibitor Enhances Anti-Tumor Effects in Desmoplastic Microenvironment.
Chang HG; Choi YH; Hong J; Choi JW; Yoon AR; Yun CO
Cells; 2021 Oct; 10(11):. PubMed ID: 34831034
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
13. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
Bieler A; Mantwill K; Dravits T; Bernshausen A; Glockzin G; Köhler-Vargas N; Lage H; Gansbacher B; Holm PS
Hum Gene Ther; 2006 Jan; 17(1):55-70. PubMed ID: 16409125
[TBL] [Abstract][Full Text] [Related]
14. Association between circadian gene
Xu H; Wang Z; Mo G; Chen H
Oncol Lett; 2018 Jun; 15(6):8945-8950. PubMed ID: 29844814
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor boosts anticancer potential of fusogenic oncolytic vaccinia virus by enhancing cell-cell fusion.
Nakatake M; Kurosaki H; Nakamura T
Cancer Sci; 2024 Feb; 115(2):600-610. PubMed ID: 38037288
[TBL] [Abstract][Full Text] [Related]
16. Complexing the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T with Cationic Nanoparticles Enhances Viral Infection and Spread in Prostate and Pancreatic Cancer Models.
Man YKS; Aguirre-Hernandez C; Fernandez A; Martin-Duque P; González-Pastor R; Halldén G
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012152
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
18. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin.
Yoon AR; Kim JH; Lee YS; Kim H; Yoo JY; Sohn JH; Park BW; Yun CO
Hum Gene Ther; 2006 Apr; 17(4):379-90. PubMed ID: 16610926
[TBL] [Abstract][Full Text] [Related]
19. [Enhancive effect of histone deacetylase inhibitor trichostatin a on transfection efficiency of adenovirus in ovarian carcinoma cell line A2780].
Chen G; Wang BB; Li FJ; Liu DY; Zhou JF; Lu YP; Ma D
Ai Zheng; 2005 Oct; 24(10):1196-200. PubMed ID: 16219132
[TBL] [Abstract][Full Text] [Related]
20. The effect of sodium butyrate and cisplatin on expression of EMT markers.
Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
